Literature DB >> 4028028

Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary.

J E Filmus, R N Buick.   

Abstract

We have identified a case of serous cystadenocarcinoma of the ovary in which the tumor cells display an amplification (from 10- to 20-fold) of the cellular oncogene K-ras. Normal cells purified from the malignant ascites did not show such amplification. Five consecutive samples were obtained by paracentesis over a 9-month period during which the patient received chemotherapy and underwent clinical progression. The level of c-K-ras amplification in the tumor cells did not change during this period. In studies of the tumors of 6 additional patients with adenocarcinoma of the ovary and 5 cell lines of the same histology, we have detected no other example of significant c-K-ras amplification.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028028

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Unexpected effects on bacterial phenotype induced by expression of a tumour-amplified human sequence.

Authors:  J Heighway; M F Santibanez-Koref
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

2.  Isolation of a human genomic fragment, co-amplified with c-Ki-ras, that affects plasmid supercoiling in E. coli.

Authors:  J Heighway; A H Geurts van Kessel
Journal:  Nucleic Acids Res       Date:  1987-04-24       Impact factor: 16.971

3.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

Review 4.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

5.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.

Authors:  B C Bastian; P E LeBoit; D Pinkel
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

6.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 7.  Predictive biomarkers in precision medicine and drug development against lung cancer.

Authors:  Bingliang Fang; Reza J Mehran; John V Heymach; Stephen G Swisher
Journal:  Chin J Cancer       Date:  2015-07-02

8.  Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.

Authors:  G Krupitza; R Fritsche; E Dittrich; H Harant; H Huber; T Grunt; C Dittrich
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

9.  Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.

Authors:  K Niwa; M Itoh; T Murase; S Morishita; N Itoh; H Mori; T Tamaya
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

10.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.